Last reviewed · How we verify
Oxycyte
At a glance
| Generic name | Oxycyte |
|---|---|
| Also known as | Oxycyte Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v, perfluorocarbon |
| Sponsor | Tenax Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Placebo Controlled, Double-Blind, Single Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of Oxycyte in Patients With Severe Non-Penetrating Traumatic Brain Injury (Phase 2)
- An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL- (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycyte CI brief — competitive landscape report
- Oxycyte updates RSS · CI watch RSS
- Tenax Therapeutics, Inc. portfolio CI